Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

Joint venture between GlaxoSmithKline and Pfizer in HIV illustrates opportunities to develop combination pills to challenge current market leaders. Nature Reviews Drug Discovery - Tapping into ...

Meanwhile, federal funding cuts and dismantled CDC HIV prevention programs could make it hard to reach the people most at risk—particularly low-income communities, women, and people of color.

HIV advocates hope lenacapavir, a long-acting, injectable HIV-prevention drug, could be a game changer in the fight against the virus. Nardus Engelbrecht / AP file Sept. 12, 2024, 9:43 AM EDT ...